MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
ChemoCentryx Operating Income 2011-2026 | CCXI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -130 M | -55.2 M | -58.3 M | -40.3 M | 16.5 M | -40.7 M | -47.7 M | -47.4 M | -39.1 M | -39.6 M | -4.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | -130 M | -44.2 M |
Quarterly Operating Income ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -31.6 M | -38.2 M | - | -21.8 M | -38.7 M | -29.3 M | - | -23.9 M | 20.4 M | -22.1 M | - | -13.6 M | -16 M | -12.5 M | - | -11.5 M | -7.48 M | -9.86 M | - | -6.91 M | -9.58 M | -6.31 M | - | -7.33 M | -10.1 M | -15.3 M | - | -11.7 M | -12.2 M | -12.1 M | - | -11.1 M | -12.4 M | -11.7 M | - | -9.55 M | -9.6 M | -10.3 M | - | -10.2 M | -11 M | -8.45 M | - | -8.65 M | -7.98 M | -6.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.4 M | -38.7 M | -13.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.21 | -0.42 % | $ 208 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-94.5 M | $ 3.35 | -2.62 % | $ 295 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 216.26 | -0.83 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 19.12 | -0.57 % | $ 894 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-17.3 M | $ 0.62 | 2.14 % | $ 7.1 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 46.45 | -0.91 % | $ 4.18 B |  Schweiz |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.4 | -0.36 % | $ 357 M | Britain |
 |
Exelixis
EXEL
|
872 M | $ 41.13 | -0.69 % | $ 11.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.63 | - | $ 16.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-84.8 M | $ 6.64 | -3.63 % | $ 421 K | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 25.59 | -0.35 % | $ 16.5 B | Danmark |
 |
Grifols, S.A.
GRFS
|
595 M | $ 7.64 | -0.72 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 61.68 | -1.88 % | $ 7.39 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 26.99 | -2.21 % | $ 1.55 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
ImmuCell Corporation
ICCC
|
-1.64 M | $ 6.43 | 0.31 % | $ 52.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Immatics N.V.
IMTX
|
-86.3 M | $ 9.32 | -2.0 % | $ 586 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-214 M | $ 69.48 | -1.85 % | $ 11.1 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.33 | -2.92 % | $ 235 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.29 | -2.94 % | $ 822 M | Canada |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |